CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...